^
Association details:
| Biomarker: | HLA-A underexpression + PD-L1 expression |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug Class: | Immunotherapy |
| Direction: | Resistant |
Evidence:
Source:
Title:
9MO - Profile of immunorecognition related markers including HLA-1 expression to predict response to immunocheckpoint inhibitors in non-small cell lung cancer
Published date:
03/23/2023
Excerpt:
Here we evaluate HLA-1 and other immune-related markers as potential predictive factors of response to ICI in NSCLC….Our work reveals that ∼45% of NSCLC in our cohort express low staining levels of HLA-1 (down regulation or total absence) compared to normal/high staining (55%). Those patients present worse clinical outcomes: mPFS to IT 9.1 (6.5–20.2) vs 21 (13.9-NR) months (p-value 0.028), respectively. We also report that HLA-1 is co-expressed with PD-L1 (p <0.005), regardless of histological subtype.
